YOLFTbeta
Korsana Biosciences, Inc.

Korsana Biosciences, Inc.

KRSA · NASDAQ · Healthcare / Biotechnology

31.65USD+0.37 (+1.18%)

Price History

Full chart

Market Stats

Previous Close31.28
Open31.79
Day Range30.46 – 32.63
52-Week Range7.19 – 59.36
Volume225.51K
Market Cap1.41B
P/E (TTM)0.00
Forward P/E0.00
EPS-7.07
Dividend Yield0.00%
Beta1.75
50-Day Avg27.89
200-Day Avg19.20

About

Korsana Biosciences, Inc., a biotechnology company that discovers and develops novel therapies for neurodegenerative diseases. The company was incorporated in 2024 and is based in Waltham, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Jonathan Violin M.B.A., Ph.D.
  • Employees19
  • Headquarters221 Crescent Street, Waltham, MA, United States, 02453, USA
  • Websitehttps://korsana.com

Leadership

  • Dr. Jonathan Violin M.B.A., Ph.D.President, CEO, Secretary & Director · b. 1975
  • Dr. Mark Joseph Vignola Ph.D.Chief Financial Officer · b. 1978
  • Dr. Gan Wei Ph.D.Chief Technical Officer
  • Ms. Madelyn Demsky ZeylikmanGeneral Counsel · b. 1974
  • Dr. Matthew Leoni M.D.Chief Medical Officer
  • Mr. Kyle Breidenstine CPA, M.B.A.Senior Vice President of Finance & Treasurer

Financials

Income Statement

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue---4.51M2.30M3.32M297.00K-2.00M2.07M
Growth (%)-----49.06%+44.60%-91.05%--+3.70%
Cost of Revenue2.17M1.75M1.53M95.14M56.41M-5.58M1.31M--
Gross Profit-2.17M-1.75M-1.53M-90.63M-54.12M3.32M-5.28M-1.31M2.00M2.07M
Gross Margin----2010.94%-2357.06%100.00%-1778.45%-100.00%100.00%
Operating Expense61.38M92.18M113.72M34.40M27.15M58.52M13.26M11.64M5.63M7.05M
Operating Income-63.55M-93.92M-115.25M-125.04M-81.27M-55.20M-18.54M-12.95M-3.63M-4.97M
Operating Margin----2774.28%-3539.42%-1662.50%-6242.42%--181.40%-239.78%
EBITDA-61.38M-92.18M-113.72M-122.34M-80.64M-53.84M-18.18M-9.58M-3.06M-3.53M
EBITDA Margin----2714.38%-3512.06%-1621.75%-6121.55%--152.85%-170.11%
Net Income-63.55M-93.92M-115.25M-123.01M-77.80M-51.65M-44.08M-5.26M-3.06M-3.53M
Net Income Margin----2729.27%-3388.59%-1555.63%-14841.08%--152.85%-170.11%
R&D50.90M78.80M87.72M95.14M56.41M37.64M5.98M1.51M286.00K959.00K
R&D as % of Total Revenue---2110.94%2457.06%1133.61%2013.13%-14.30%46.24%
Interest Expense-----16.00K----
Interest Expense % of Total Revenue-----0.48%----

Balance Sheet

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-5.47M7.40M186.48M115.38M59.33M18.08M13.37M9.57M9.98M
Total Liabilities-14.04M17.85M88.75M55.88M11.09M7.63M2.09M725.00K900.00K
Total Equity--8.57M-10.45M97.73M59.49M48.25M10.45M11.29M8.85M9.09M
Cash---97.59M54.40M53.96M13.38M7.57M3.23M3.24M
Total Debt---73.92M45.73M-----
Net Debt----23.68M-8.66M-53.96M-13.38M-7.57M-3.23M-3.24M

Cash Flow

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-49.87M-81.22M-97.50M-102.22M-72.49M-36.52M-40.61M-21.25M-4.33M-3.31M
Investing Cash Flow-1.45M-1.40M-3.44M-6.71M18.00K1.46M-10.40M--
Financing Cash Flow51.32M82.62M100.94M211.57M28.09M30.79M29.00K5.02M10.06M3.32M
Capital Expenditure1.45M1.40M3.44M6.89M1.52M7.00K0000
Free Cash Flow-51.32M-82.62M-100.94M-109.10M-74.01M-36.52M-40.61M-21.25M-4.33M-3.31M
FCF to OCF102.90%101.73%103.53%106.74%102.10%100.02%100.00%100.00%100.00%100.00%

Earnings

Report DateMay 29, 2019Aug 12, 2019Dec 27, 2019Feb 26, 2020Jun 3, 2020Aug 3, 2020Nov 5, 2020Feb 25, 2021Jun 2, 2021Jul 30, 2021Nov 9, 2021Feb 25, 2022May 5, 2022Aug 9, 2022Nov 9, 2022Mar 22, 2023May 12, 2023Aug 8, 2023Nov 8, 2023Feb 22, 2024May 1, 2024Aug 6, 2024Nov 29, 2024Mar 19, 2025May 30, 2025Aug 29, 2025Nov 28, 2025Mar 25, 2026May 29, 2026Aug 31, 2026Nov 11, 2026
EPS Estimate----------------------------0.38---0.98
EPS Actual-190.99-164.84-139.40-132.17-102.35-98.40-82.06-79.06-55.04-63.45-36.51-34.75-41.84-43.13-33.79-23.21-22.37-12.8321.75-4.79-4.33-3.69-2.001.46-3.91-0.74-2.12-0.19-5.29-2.89-
Surprise---------------------------50.00%---
Timing-------------------------------

Key Statistics & Ratios

Market Cap1.41B
Enterprise Value1.35B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book0.00
EPS-7.07
Book Value-7.84
Revenue (TTM)0
Gross Profit (TTM)0
Profit Margin0.00%
Operating Margin0.00%
Return on Equity0.00%
Return on Assets0.00%
Shares Outstanding45.54M
Shares Float4.31M
Beta1.75
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Sep 9, 20261:7
  • May 16, 20231:20